InVivoMab anti-mouse 4-1BB (CD137) BE0169-R001mg from Bio X Cell | Biocompare.com

Supplier Images

InVivoMab anti-mouse 4-1BB (CD137)

(1)

Citations:

Supplier Page from
Bio X Cell for
InVivoMab anti-mouse 4-1BB (CD137)

Bio X Cell's InVivoMab anti-mouse 4-1BB (CD137) is a Rat monoclonal antibody. The InVivoMab anti-mouse 4-1BB (CD137) Antibody was generated using TNFRSF9 as the antigen. It reacts with Mouse. This antibody has been shown to work in applications such as: In Vivo, and Other.

Description

Bio X Cell InVivoMAb anti-mouse 4-1BB (CD137) Monoclonal Antibody has the following reported applications: in vivo activation of 4-1BB. It features greater than 95% purity, ultra-low endotoxin levels, and are preservative, stabilizer, and carrier protein-free

Product Specs
ItemInVivoMab anti-mouse 4-1BB (CD137)
CompanyBio X Cell
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberBE0169-R001mg
Quantity1 mg
Applicationsin vivo activation of 4-1BB
ConcentrationLot specific,typically between 4-11 mg/ml
Conjugate/TagUnconjugated
ReactivityMouse
Target4-1BB
IsotypeIgG1, κ
CloneLOB12.3
Hostrat
NCBI Full Gene Nametumor necrosis factor receptor superfamily, member 9
NCBI Gene Aliases4-1BB, A930040I11Rik, CDw137, Cd137, ILA, Ly63
ClonalityMonoclonal
ImmunogenMouse CD137 human Fc fusion protein
Antibody TypePrimary Antibody
Purity>95%, Determined by SDS-PAGE
FormatPBS, pH 8.0, Contains no stabilizers or preservatives
Research AreaCancer Biology, Immune Checkpoint Protein, Immunology

Specifications/Features

Other available quantities: Available in 1, 5, 10, 25, 50, 100 mg and bulk sizes. Academic discount available.

Endotoxin: <2EU/mg (<0.002EU/µg), Determined by LAL gel clotting assay

Add to Compare List

Bio X Cell

Bio X Cell

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bxcell.com

Company Profile

Website: bioxcell.com

(1) Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinityNature communicationsMay 20, 2019Qi X, Li F, Wu Y, Cheng C, Han P, Wang J, Yang X.

(2) Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccineProceedings of the National Academy of Sciences of the United States of AmericaSeptember 22, 2015Bartkowiak T, Singh S, Yang G, Galvan G, Haria D, Ai M, Allison JP, Sastry KJ, Curran MA.

(3) Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodiesClinical cancer research : an official journal of the American Association for Cancer ResearchMarch 1, 2015Dai M, Yip YY, Hellstrom I, Hellstrom KE.

(4) Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in miceBloodApril 3, 2014Murphy JT, Burey AP, Beebe AM, Gu D, Presta LG, Merghoub T, Wolchok JD.

(5) Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancerJournal of translational medicineSeptember 17, 2013Guo Z, Cheng D, Xia Z, Luan M, Wu L, Wang G, Zhang S.

(6) CD4+ T cells develop antiretroviral cytotoxic activity in the absence of regulatory T cells and CD8+ T cellsJournal of virologyJune 1, 2013Manzke N, Akhmetzyanova I, Hasenkrug KJ, Trilling M, Zelinskyy G, Dittmer U.

(7) Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammationJournal of immunotherapy (Hagerstown, Md. : 1997)May 1, 2013Dai M, Wei H, Yip YY, Feng Q, He K, Popov V, Hellstrom I, Hellstrom KE.

(8) Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunityCancer researchMarch 1, 2013Kwong B, Gai SA, Elkhader J, Wittrup KD, Irvine DJ.

(9) Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatinPloS oneJanuary 1, 2013Wei H, Zhao L, Li W, Fan K, Qian W, Hou S, Wang H, Dai M, Hellstrom I, Hellstrom KE, et al.

(10) Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine productionPloS oneApril 29, 2011Curran MA, Kim M, Montalvo W, Al-Shamkhani A, Allison JP.

(11) Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responsesEuropean journal of immunologyDecember 1, 2002Taraban VY, Rowley TF, O'Brien L, Chan HT, Haswell LE, Green MH, Tutt AL, Glennie MJ, Al-Shamkhani A.

(1)

5/3/2018Anti-CD137 Agonistic Antibody Treatment Anna MalyshkinaAgonistic anti-CD137 antibodies have been already reported to induce T cell mediated antitumor immunity. The aim of our experiments was to study if this anti-tumor activity is lost in the settings of ... Read Review